

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: IFT2/17 - Immunophenotypisation

Dead line: 30.10.2017

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U_{AV} = expanded uncertainty of the assigned value ($k = 2$)	

Test	[unit]	Comparability						AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
		RoM	SD	CV [%]	N_{tot}	N_{out}									
(253) CD 3+ T lymphocytes												100	82	82%	
Samples and groups	[%]				100										
Sample A		53,5	1,7	3,2	100	CVP	53,5	0,42	7%	49,7	57,3	100	84	84%	
(12) Beckman Coulter		53,9	1,5	2,7	61							61			
(88) Becton Dickinson		52,8	2,2	4,1	39							39			
Sample B		71,3	1,8	2,5	100	CVP	71,3	0,44	7%	66,3	76,3	100	96	96%	
(12) Beckman Coulter		71,4	1,5	2,1	61							61			
(88) Becton Dickinson		71,0	2,4	3,4	39							39			
(254) CD 4+ T lymphocytes												100	88	88%	
Samples and groups	[%]				100										
Sample A		38,2	1,7	4,5	100	CVP	38,2	0,42	10%	34,3	42,1	100	90	90%	
(12) Beckman Coulter		38,5	1,7	4,4	61							61			
(88) Becton Dickinson		37,8	1,7	4,6	39							39			
Sample B		46,7	1,5	3,3	100	CVP	46,7	0,38	10%	42	51,4	100	95	95%	
(12) Beckman Coulter		46,9	1,2	2,5	61							61			
(88) Becton Dickinson		46,0	2,3	5,1	39							39			
(255) CD 8+ T lymphocytes												100	88	88%	
Samples and groups	[%]				100										
Sample A		13,7	0,93	6,8	100	CVP	13,7	0,23	17%	11,3	16,1	100	92	92%	
(12) Beckman Coulter		13,7	0,79	5,7	60							60			
(88) Becton Dickinson		13,6	1,2	8,8	40							40			
Sample B		20,0	1,5	7,3	100	CVP	20	0,36	17%	16,6	23,4	100	94	94%	
(12) Beckman Coulter		19,7	1,3	6,8	60							60			
(88) Becton Dickinson		20,4	1,5	7,4	40							40			
(256) B lymphocytes												100	83	83%	
Samples and groups	[%]				100										
Sample A		2,95	0,46	16	100	CVP	2,95	0,11	30%	2,06	3,84	100	87	87%	
(12) Beckman Coulter		2,88	0,53	18	61							61			
(88) Becton Dickinson		3,04	0,33	11	39							39			
Sample B		12,9	1,2	9,2	100	CVP	12,9	0,29	30%	9,03	16,8	100	93	93%	
(12) Beckman Coulter		12,6	1,4	11	61							61			
(88) Becton Dickinson		13,3	0,87	6,5	39							39			
(257) NK cells												100	94	94%	
Samples and groups	[%]				100										
Sample A		42,3	2,2	5,1	100	CVP	42,3	0,53	26%	31,3	53,3	100	98	98%	
(12) Beckman Coulter		41,8	1,9	4,4	61							61			
(88) Becton Dickinson		42,9	2,3	5,3	39							39			
Sample B		13,7	1,5	11	100	CVP	13,7	0,37	26%	10,1	17,3	100	94	94%	
(12) Beckman Coulter		13,4	1,4	10	61							61			
(88) Becton Dickinson		14,2	1,6	12	39							39			

st_kn_p

End of report

Printed: 01.11.2017